Management of severe COPD exacerbations: focus on beclomethasone dipropionate/formoterol/glycopyrronium bromide

Marco Mantero¹,²
Dejan Radovanovic³
Pierachille Santus³
Francesco Blasi¹,²

¹Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy; ²Internal Medicine Department, Respiratory Unit and Regional Adult Cystic Fibrosis Center, IRCCS Fondazione Ca’ Granda Ospedale Policlinico, Milan, Italy; ³Department of Biomedical and Clinical Sciences (DIBIC), Pulmonary Unit, University of Milan, Ospedale L. Sacco, ASST Fatebenefratelli-Sacco, Milan, Italy

Abstract: The major determinant of the decline in lung function, quality of life, and the increased mortality risk in patients with COPD is represented by severe acute exacerbations of the disease, that is, those requiring patients’ hospitalization, constituting a substantial social and health care burden in terms of morbidity and medical resource utilization. Different long-term therapeutic strategies have been proposed so far in order to prevent and/or reduce the clinical and social impact of these events, the majority of which were extrapolated from trials initially focused on the effect of long-acting muscarinic antagonist and subsequently on the efficacy of long-acting β2-agonists in combination or not with inhaled corticosteroids. The option to employ all three classes of molecules combined, despite the limited amount of evidence in our possession, represents a choice currently proposed by international guidelines; however, current recommendations are often based mainly on observational studies or on the results of secondary outcomes in randomized controlled trials. The present narrative review evaluates the available trials that investigated the efficacy of inhaled therapy to prevent COPD exacerbations and especially severe ones, with a particular focus on beclomethasone dipropionate/formoterol/glycopyrronium bromide fixed dose combination, which is the first treatment that comprises all the three drug classes, specifically tested for the prevention of moderate and severe COPD exacerbations.

Keywords: hospitalization, COPD, triple therapy, inhaled corticosteroids, formoterol, glycopyrronium

Introduction

Acute exacerbations of COPD (AECOPDs) represent an acute event characterized by a rapid worsening of a patient’s clinical state that requires a medical intervention of different intensity depending on the severity of the event and on the patient’s basic condition.¹ The real incidence of these events is difficult to measure, especially for the less severe cases that are certainly underestimated and underreported, being often documented in <50% of cases.²

The cost of AECOPDs represents the 50% of the direct economic burden of COPD;³ however, the cost increases up to 70% for exacerbations that require hospitalization¹ — that is, severe exacerbations — and for the management of early recurrence, with a leading increasing cost of 18%.⁴

The prognosis of patients with COPD is influenced by the severity and recurrence of the exacerbation, with 1-year mortality rates ranging from 11% for patients who need hospitalization² to 50% for patients subjected to mechanical ventilation.⁵ On the contrary, mortality increases up to 37% when hospitalization is needed in case of recurrent AECOPD.⁷ A prospective management strategy aimed at reducing
the severity and the number of AECOPDs, with a particular focus on moderate and severe exacerbations, is needed in order to improve the patients’ prognosis in terms of quality of life (QoL), disease progression and mortality, as well as the reduction in health care costs and the overall economic and social disease burden.

Nowadays, a consistent number of treatments have demonstrated this ability and are therefore suggested for the reduction of the rate and severity of acute exacerbations in patients with COPD. Nonetheless, to date, outcome-driven evidence coming from randomized clinical trials are limited, often leaving to the individual the clinical decision-making on the choice for the most appropriate treatment strategy to be used for patients with COPD at risk of exacerbation.

This narrative review explores the current evidence about the available pharmacological treatments for the prevention of AECOPDs, with a special focus on triple therapy and in particular on the combination of beclomethasone dipropionate (BDP)/formoterol (FORM)/glycopyrronium bromide (GLY).

**Role of inhaled corticosteroids (ICS) containing therapies in the prevention of exacerbations**

The indications for ICS containing therapies for patients with COPD have greatly changed during the last 15 years. Earlier, the widespread use of long-acting β2-agonists (LABA) in combination with ICS was initially based upon the evidence of their efficacy in reducing AECOPD and hospitalizations.3,9 Subsequently, the UPLIFT trial demonstrated that also tiotropium (TIO), the first approved long-acting muscarinic antagonist (LAMA), was able to reduce the risk of AECOPD, making it a valid and safe alternative to the therapy with ICS/LABA.10,11

Previously, the growing evidence about efficacy and safety of LABA/LAMA fixed combinations and the increased risk of pneumonia linked with ICS-containing regimens further restricted the indication for ICS therapy, which was confirmed in patients at high risk of AECOPD that remained asymptomatic or had severe airflow obstruction despite an initial trial with LABA/LAMA combinations.

The last release of the GOLD recommendations1 suggests that COPD patients at high risk of exacerbations – that is, patients with two or more AECOPD in the last 12 months – may benefit from the triple therapy, although the initial approach should always be based upon LABA/LAMA. Recently, expert opinion-based algorithms suggested that patients who would benefit more from ICS-containing therapies were patients with asthma–COPD overlap or with increased blood eosinophil counts.12,13

The indication toward the efficacy of ICS in preventing AECOPD, and especially severe exacerbations leading to hospitalization, has not always been inferred from randomized controlled trials (RCTs) that had as a primary outcome a reduction in the exacerbations rate. Moreover, throughout the years, the heterogeneity of patients enrolled and a non-unequivocal definition of exacerbation determined contrasting results or data difficult to be interpreted in light of a real-life setting (Table 1).

In 2007, the results of the Towards a Revolution in COPD Health (TORCH) study were published.6 This was the first study that tested the twice daily (BID) fluticasone propionate/salmeterol (FP/SALM) 500/50 μg combination treatment in a consistent number of COPD patients. The primary outcome of the trial was mortality rate, which was not met, but at the end of the 3-year follow-up, patients in the combination treatment group had the lowest annual rate ratio of moderate and severe exacerbations (~25% vs placebo). The annual rate ratio for the FP/SALM arm was also significantly lower compared with SALM or FP alone (risk ratio [RR] 0.88 and 0.91, respectively). The advantage of the combination treatment over SALM alone, however, seemed to be no longer present when severe exacerbations were separately considered. Nonetheless, the trial proved that ICS-containing regimens, but not ICS alone, were efficacious in reducing hospitalization due to severe AECOPDs, improving QoL and lung function in patients with moderate to severe COPD.

In the same year, the Canadian Optimal Therapy of COPD Health (TORCH) study were published.6 This was the first study that tested the twice daily (BID) fluticasone propionate/salmeterol (FP/SALM) 500/50 μg combination treatment in a consistent number of COPD patients. The primary outcome of the trial was mortality rate, which was not met, but at the end of the 3-year follow-up, patients in the combination treatment group had the lowest annual rate ratio of moderate and severe exacerbations (~25% vs placebo). The annual rate ratio for the FP/SALM arm was also significantly lower compared with SALM or FP alone (risk ratio [RR] 0.88 and 0.91, respectively). The advantage of the combination treatment over SALM alone, however, seemed to be no longer present when severe exacerbations were separately considered. Nonetheless, the trial proved that ICS-containing regimens, but not ICS alone, were efficacious in reducing hospitalization due to severe AECOPDs, improving QoL and lung function in patients with moderate to severe COPD.
<table>
<thead>
<tr>
<th>Trial</th>
<th>Intervention</th>
<th>Severity (mean ± SD FEV&lt;sub&gt;1&lt;/sub&gt;)</th>
<th>Primary outcome</th>
<th>Secondary outcome</th>
<th>QoL (mean ± SD)</th>
<th>AECOPD definition</th>
<th>AECOPD history</th>
<th>AECOPD annual rate</th>
<th>Reduction in AECOPD risk</th>
<th>Overall risk of death</th>
</tr>
</thead>
<tbody>
<tr>
<td>TORCH&lt;sup&gt;7&lt;/sup&gt; (N=6,112) 152 w</td>
<td>FFVI 500/50 BID; SALM 50 OD; FF 500 BID; placebo</td>
<td>Moderate or severe</td>
<td>All-cause mortality</td>
<td>Frequency of moderate/severe AECOPD; QoL</td>
<td>SGRQ: 49±17</td>
<td>Symptomatic deterioration requiring ABT, SCS, hospitalization, or a combination of these, and health status</td>
<td>Moderate: 1.0±1.4 Severe: 0.2±0.6</td>
<td>FP/SALM vs placebo: 0.85 vs 1.13</td>
<td>Moderate or severe FP/SALM vs placebo, RR 0.75 (95% CI 0.69–0.81; P&lt;0.001); Severe RR 0.83 (95% CI 0.71–0.98; P=0.03)</td>
<td>FP/SALM vs placebo RR 0.825 (95% CI 0.681–1.002; P=0.052)</td>
</tr>
<tr>
<td>SUMMIT&lt;sup&gt;4&lt;/sup&gt; (N=16,458) event driven</td>
<td>FFVI 100/25 OD; FF 100 OD; VI 25 OD; placebo</td>
<td>Frequency of moderate/severe exacerbations</td>
<td>Rate of FEV&lt;sub&gt;1&lt;/sub&gt;, decline; cardiovascular events; frequency of moderate/severe exacerbations</td>
<td>SGRQ range (N=4,443): 45–46</td>
<td>Moderate AECOPD: ≥2 AECOPD: 39%</td>
<td>Not reported</td>
<td>Not reported</td>
<td>FF/VI vs placebo HR 0.88 (95% CI 0.74–1.04)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>INSPIRE&lt;sup&gt;5&lt;/sup&gt; (N=1,323) 104 w</td>
<td>FP/SALM 500/50 BID vs TIO 18 OD</td>
<td>Frequency of moderate/severe exacerbations</td>
<td>Rate of health care utilization (OCS/Hosp)</td>
<td>SGRQ range: 50.3–52.3</td>
<td>Worsening of symptoms that required treatment with SCS or ABT or hospitalization</td>
<td>≥1 AECOPD: 85% FP/SALM, 88% TIO</td>
<td>Not reported</td>
<td>FP/SALM vs TIO: moderate 1.28 vs 1.32, RR 0.97 (95% CI 0.84–1.12; P=0.656); severe 16% vs 13% (P=0.085)</td>
<td>Not reported</td>
<td></td>
</tr>
<tr>
<td>UPLIFT&lt;sup&gt;6&lt;/sup&gt; (N=5,993) 208 w + 30 d FU</td>
<td>TIO 18 OD vs placebo (ICS withdrawal) 62% at baseline</td>
<td>Rate of FEV&lt;sub&gt;1&lt;/sub&gt;, decline and bronchodilator response from d 30 to end of study</td>
<td>Rate of FVC or SVC decline, SGRQ, all-cause mortality, time to first moderate or severe AECOPD</td>
<td>Not reported</td>
<td>An increase in or the new onset of more than one respiratory symptom (cough, sputum, purulence, wheezing, dyspnea) for ≥3 d or need for SCS/ABT</td>
<td>TIO vs placebo: −14% (P&lt;0.001)</td>
<td>TIO vs placebo HR 0.89 (95% CI 0.79–1.02; P=0.09)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>WISDOM&lt;sup&gt;6&lt;/sup&gt; (N=2,485) 52 w</td>
<td>ICS withdrawal (SALM 50 BID + TIO 18 OD) and ICS continuation (FP/SALM 500/50 BID and TIO 18 OD)</td>
<td>≥1 AECOPD last 12 mo before enrolment</td>
<td>Time to first severe AECOPD, No of moderate or severe exacerbations</td>
<td>SGRQ (2.262): 46±18</td>
<td>Moderate AECOPD: an increase in LRT symptoms or the new onset of ≥2 symptoms, with at least one lasting ≥3 d and need for ABT/SCS. Severe AECOPD: hospitalization</td>
<td>≥2 moderate or severe: withdrawal: −14%, continuation: −13%</td>
<td>Not reported</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

(Continued)
<table>
<thead>
<tr>
<th>Trial</th>
<th>Intervention</th>
<th>Severity (mean ± SD FEV(_1))</th>
<th>Primary outcome</th>
<th>Secondary outcome</th>
<th>QoL (mean ± SD)</th>
<th>AECOPD definition</th>
<th>AECOPD history</th>
<th>AECOPD annual rate</th>
<th>Reduction in AECOPD risk</th>
<th>Overall risk of death</th>
</tr>
</thead>
<tbody>
<tr>
<td>FLAME (^{13})</td>
<td>IND/GLY</td>
<td>110/50 OD; FP/SALM 500/50</td>
<td>FU</td>
<td>17 (N=3,362) 52 w + 30 d BID</td>
<td>44%±9%</td>
<td>Non-inferiority of IND/GLY in reducing annual rate of all AECOPD; if primary aim succeeded, demonstrate IND/GLY superiority vs FP/SALM</td>
<td>SGRQ: 47±16</td>
<td>Anthonisen criteria: Mild AECOPD: worsening of symptoms for &gt;2 d but no SCS/ABT. Moderate AECOPD: need for SCS/ABT. Severe AECOPD: hospitalization/ED + SCS/ABT</td>
<td>≥1 AECOPD last 12 mo before enrolment</td>
<td>Moderate or severe, IND/GLY vs FP/SALM: 0.98 (95% CI 0.88–1.10) vs 1.19 (95% CI 1.07–1.32), RR 0.83 (95% CI 0.75–0.91, (P&lt;0.001))</td>
</tr>
<tr>
<td>TRILOGY (^{18})</td>
<td>BDP/FORM/GLY</td>
<td>BID 100/6/12.5 vs BDP/FORM 100/6 BID</td>
<td>36.5%±8.5%</td>
<td>18 (N=1,368) 52 w</td>
<td>Pre-dose FEV(_1), at all visits; FEV(_1) response (change from baseline &gt;100 mL) at w 26 and w 52; TDI and SGRQ at all visits; % days without need of rescue medication; moderate/severe AECOPD frequency; time to the first moderate/severe AECOPD</td>
<td>Baseline SGRQ not reported; CAT: 20.8±5.8</td>
<td>According to EMA/Committee for Medicinal Products for Human Use guidelines</td>
<td>1.2 (range 1–6)</td>
<td>Moderate/severe AECOPD, BDP/FORM/GLY vs BDP/FORM: 0.41 vs 0.53, RR 0.77 (95% CI 0.65–0.92; (P&lt;0.005))</td>
<td>Not reported</td>
</tr>
<tr>
<td>FULFIL (^{19})</td>
<td>FF/UMEC/VI</td>
<td>100/62.5/25 OD vs BUD/FORM 400/12 BID</td>
<td>45.3%±13.3%</td>
<td>19 (N=1,810) 24 w</td>
<td>Co-primary: trough FEV(_1), at w 24 (ITT) and w 52 (EXT); change from baseline SGRQ at w 24 (ITT) and w 52 (EXT)</td>
<td>Trough FEV(_1), response (change from baseline &gt;100 mL) at w 2 (ITT) and w 52 (EXT); change from baseline SGRQ at every visit; change from baseline E-RS score at w 24 (ITT) and w 52 (EXT)</td>
<td>SGRQ (ITT): 51.4±16.5</td>
<td>Mild AECOPD: self-managed by patients’ increasing rescue medication use. Moderate AECOPD: need SCS/ABT. Severe AECOPD: need for hospitalization</td>
<td>2 moderate AECOPD or 1 severe AECOPD in last 12 mo</td>
<td>FF/UMEC/VI vs BUD/FORM: 0.20 vs 0.36, RR 0.56 (95% CI 0.37–0.85; (P=0.006))</td>
</tr>
<tr>
<td>Trial</td>
<td>Group 1</td>
<td>Group 2</td>
<td>Follow-up</td>
<td>Endpoint 1</td>
<td>Endpoint 2</td>
<td>Endpoint 3</td>
<td>Endpoint 4</td>
<td>Endpoint 5</td>
<td>Endpoint 6</td>
<td>Endpoint 7</td>
</tr>
<tr>
<td>-------</td>
<td>---------</td>
<td>---------</td>
<td>-----------</td>
<td>------------</td>
<td>------------</td>
<td>------------</td>
<td>------------</td>
<td>------------</td>
<td>------------</td>
<td>------------</td>
</tr>
<tr>
<td>TRINITY (N=2,691)</td>
<td>BDP/FORM/GLY 100/6/12.5 BID</td>
<td>vs BDP/FORM 100/6 BID + TIO 18 OD</td>
<td>52 w</td>
<td>No of moderate/severe AECOPD at w 52</td>
<td>Pre-dose FEV₁ at w 52; time to first moderate/severe AECOPD; time to severe AECOPD; rate of severe AECOPD; FEV₁ response (change from baseline &gt;100 mL) at w 26 and w 52; pre-dose ICS at all visits; SGRQ; % days without need of rescue medication</td>
<td>according to EMA/Committee for Medicinal Products for Human Use guidelines</td>
<td>≥1 moderate/severe AECOPD in last 12 mo</td>
<td>BDP/FORM/GLY vs BDP/FORM vs TIO: 0.46 vs 0.45 vs 0.57. RR triple vs TIO 0.80 (95% CI 0.62–0.92; P=0.0025)</td>
<td>Moderate/severe: Not reported</td>
<td></td>
</tr>
<tr>
<td>IMPACT (N=10,355)</td>
<td>FF/UMEC/vI 100/62.5/25</td>
<td>vs FF/vI vs UMEC/vI</td>
<td>52 w</td>
<td>Trough FEV₁; Time to first AECOPD; Time to first AECOPD among patients with &gt;150 eosinophils/μL</td>
<td>Trough FEV₁; SGRQ</td>
<td>Time to first AECOPD; Time to first severe AECOPD; Pre-dose FEV₁, Pre-dose FVC; SGRQ; FEV₁ change &gt;100 mL</td>
<td>Annual rate of moderate/severe AECOPD at w 52</td>
<td>Moderate AECOPD: ≥2 moderate AECOPD; AECOPD: 47% worsening of symptoms with need treatment with SCS/ABT. Severe AECOPD: ≥2 severe AECOPD; AECOPD: 4% need for hospitalization or death</td>
<td>FF/UMEC/vI 0.91/year vs FF/vI 1.07/year in FF/vI (RR 0.85; 95% CI 0.80–0.90); UMEC/vI 1.21/year (RR 0.75; 95% CI 0.70–0.81)</td>
<td>Not reported</td>
</tr>
<tr>
<td>TRIBUTÉ (N=1,314)</td>
<td>BDP/FORM/GLY 100/6/9 BID</td>
<td>vs IND/GLY 85/43</td>
<td>52 w</td>
<td>Annual rate of moderate/severe AECOPD at w 52</td>
<td>Time to first AECOPD</td>
<td>Time to first severe AECOPD</td>
<td>Pre-dose FEV₁, Pre-dose FVC; SGRQ; FEV₁ change &gt;100 mL</td>
<td>Sustained worsening of respiratory symptoms that required treatment according to EMA/Committee for Medicinal Products for Human Use guidelines</td>
<td>1 moderate or severe AECOPD: 0.50 per patient per year (95% CI 0.45–0.57) vs IND/GLY: 0.59 (95% CI 0.53–0.67)</td>
<td>BDP/FORM/GLY: 0.59 vs IND/GLY: –15% (P=0.043)</td>
</tr>
</tbody>
</table>

**Abbreviations:** % pred, percent predicted value; ABT, antibiotic therapy; AECOPD, acute exacerbations of COPD; BID, twice daily; BUD, budesonide; CAT, COPD assessment test; EMA, European Medicines Agency; EXT, extended population; FEV₁, forced expiratory volume in 1 second; FF, fluticasone furoate; FORM, formoterol; FP, fluticasone propionate; FVC, forced vital capacity; GLY, glycopyrronium; HR, hazard ratio; ICS, inhaled corticosteroids; IND, indacaterol; ITT, intention to treat population; LRT, low respiratory tract; mo, months; OD, once daily; PEF, peak expiratory flow; QoL, quality of life; RR, risk ratio; SALM, salmeterol; SCS, systemic corticosteroids; SGRQ, S George Respiratory Questionnaire; TIO, tiotropium; UMEC, umeclidinium; VI, vilanterol; w, weeks.
a deterioration of symptoms that required the use of systemic corticosteroids, antibiotics, or hospitalizations.

The INSPIRE was the first study designed to compare an ICS-containing regimen and the well-established efficacy of TIO in the exacerbation rate in severe patients with COPD.\textsuperscript{15} It was a 2-year multicenter, randomized double-blind, double dummy controlled trial aimed at comparing the efficacy of FP/SALM 500/50 µg BID and TIO 18 µg on the rate of moderate and severe COPD exacerbations over a 2-year period. The authors found no difference between the two treatment regimens, when both moderate and severe AECOPD were grouped and considering AECOPD leading to hospitalization. Although the study was not powered to detect such differences, patients treated with the ICS-containing regimen demonstrated a reduced mortality rate and better QoL compared with TIO.\textsuperscript{15} The INSPIRE was the first study to use two parallel definitions of COPD exacerbation: the first was event-based, defined as the requirement of health care resources, while the second one was symptom-based, according to the 1987 Anthonisen criteria.\textsuperscript{15}

Given the aforementioned results and based on the evidence that the association of an ICS/LABA and TIO may provide additional clinical benefits than either the treatment alone in the real-life scenario, patients with severe airflow obstruction (forced expiratory volume in 1 second [FEV\textsubscript{1}] <50%) were commonly treated with the combination of TIO and an ICS-containing regimen.\textsuperscript{24,25} The CLIMB (Evaluation of Efficacy and Safety of Symbicort as add-on Treatment to Spiriva in Patients with Severe COPD) trial was designed to provide clinical efficacy and safety data about the triple therapy regimen.\textsuperscript{24,25} This was a 12-week double-blind, parallel group RCT in which, after a run-in period on TIO 18 µg, patients with severe COPD (post-bronchodilator FEV\textsubscript{1} <50% predicted) were randomized to receive also budesonide (BUD)/FORM 320/9 µg or a matching placebo.\textsuperscript{24,25} The primary outcome was functional and consisted of the change in pre-morning dose of FEV\textsubscript{1} from baseline to week 12. The study met the primary outcome, demonstrating the superiority of the triple regimen in improving lung function in terms of both airflow obstruction and air trapping. Among the secondary outcomes, severe exacerbations were analyzed, and the combination of BUD/FORM with TIO seemed superior to TIO alone, decreasing the rate of severe AECOPD by 62%.\textsuperscript{24,25} Time to first exacerbation and time to first hospitalization were also reduced for the study arm treated with the triple regimen. The CLIMB study was not powered to effectively detect clinical meaningful differences in exacerbation rates, and due to the limited study duration, the results obtained, although impacting, were not sufficient to confirm their long-term validity. Further and not confirming results came from a 6-month RCT that compared FP/SALM 500/50 µg BID added to TIO 18 µg and TIO alone in COPD patients with moderate to severe airflow obstruction.\textsuperscript{26} Also in this case, the primary outcome was based on lung function, while the effect on exacerbations was only a secondary endpoint. While proving the superiority of the free association of FP/SALM and TIO in lung function outcomes, the study failed to demonstrate any difference between the two treatments in terms of exacerbation rate. Similarly, the GLISTEN trial,\textsuperscript{27} although of limited duration and not sufficiently powered for the detection of exacerbation rate difference between the study groups, showed that the free association of GLY 44 µg and FP/SALM 500/50 µg BID was not different in terms of exacerbation rate compared with TIO and FP/SALM or FP/SALM alone.

It is important to note that none of the mentioned RCTs had, among their inclusion criteria, a consistent history of exacerbations. To enter the TORCH study, patients had to have at least one exacerbation in the previous 12 months, while for the INSPIRE trial, the positive history of AECOPD was not numerically specified. The study by Hanania et al,\textsuperscript{26} on the contrary, reported that on average only 24% of patients had at least one AECOPD in the 12 months before enrolment, making difficult to draw any clinical conclusion on exacerbation-related data.

Soon later, Short et al performed the first retrospective cohort analysis aimed at comparing the risk of exacerbation and mortality in patients treated with ICS/LABA plus TIO or ICS/LABA alone.\textsuperscript{28} The triple therapy regimen resulted to reduce the risk of exacerbation by 29% and the hospital admissions by 15% compared with ICS/LABA alone during an average follow-up of 4.65 years.\textsuperscript{28} The triple therapy also proved to reduce the all-cause mortality by 35% compared with ICS/LABA.\textsuperscript{28} The study was limited by its retrospective and observational design, but provided further indirect evidence that a combination of a LAMA with a ICS/LABA could be beneficial in terms of AECOPD prevention.\textsuperscript{28}

The introduction of the first ultra-LABA indacaterol (IND) made it possible to test for the first time whether a combination of LAMA glycopyrronium with IND was able to reduce the risk of exacerbations in patients with severe COPD compared with GLY or TIO alone.\textsuperscript{29} The primary aim of the SPARK study\textsuperscript{29} was to demonstrate the superiority of the fixed dose association of IND and GLY in reducing the rate of moderate or severe AECOPD.
compared with GLY. The duration of the study was 64 weeks (that could be prolonged up to 76 weeks), and the study enrolled patients with a severe airflow obstruction and with at least one AECOPD in the previous 12 months. The LABA/LAMA treatment seemed to be superior in reducing moderate or severe exacerbations (−12%), mild exacerbations (−15%), and all exacerbations considered together (−15%) compared with GLY alone. However, there was no statistical difference in the rate of severe exacerbations, both compared with TIO and GLY.

In light of the equivalent effect on AECOPD demonstrated in the INSPIRE trial and the significant effect of the LAMA/LABA combination, although limited mainly on mild exacerbation when compared with TIO, the FLAME study was designed to offer a direct comparison between the LABA/LAMA IND/GLY once daily (OD) and FP/SALM 500/50 μg BID in a 52-week RCT. Accordingly, the authors’ primary objective was to demonstrate the non-inferiority of the double bronchodilator regimen compared with the ICS/LABA and that the primary outcome consisted of the annual rate of all AECOPD (including mild, moderate, and severe). Included patients had a FEV1 between 25% and 60% predicted and at least one exacerbation in the 12 months prior to enrolment in the study. A significant reduction in the rate of all AECOPDs was found in patients treated with IND/GLY group (intention to treat [ITT] population RR 0.89 (0.83–0.96), P=0.003); this was also true for the time to first exacerbation, for which the LABA/LAMA regimen proved to be superior to FP/SALM both in moderate or severe and in severe AECOPD considered separately. However, subgroup analyses, especially including patients with very severe airflow obstruction, symptomatic patients at low risk of exacerbations (GOLD group B), and patients with two or more exacerbations in the previous year (the so-called frequent exacerbators), showed a possible role of ICS-containing regimens.

Studies published before the FLAME trial demonstrated a possible correlation between the peripheral eosinophil level and the response to ICS in AECOPD reduction. Contrary to what is expected, the FLAME trial demonstrated a similar effect of the two treatment regimens in patients with both <2% and >2% of serum eosinophils. The same was reported to be true for cutoff values other than 2% that were tested. All considered, in the “pre-triple” fixed dose combination (FDC) era, the evidence of the efficacy of ICS-containing regimens in terms of reduction of AECOPD risk was mostly derived from data from the secondary outcomes and extrapolated from studies comparing an ICS/LABA with a LABA alone. Prospective RCT that investigated free combination therapies with a LAMA and an ICS/LABA did not provide definitive proofs of the superiority of the triple therapy compared with ICS/LABA FDC.

Main characteristics and results of the largest RCTs are summarized in Table 1.

**Focus on FORM, GLY, and BDP**

**Pharmacokinetics and pharmacodynamics of FORM**

FORM (eformoterol in the UK) is a β2-adrenoreceptor agonist approved by the European Medicine Agency and the Food and Drug Administration for the maintenance treatment of COPD and asthma. It is a phenylethanolamine derivative, a pure diastereomer of the R,R- and S,S-enantiomers of 2-hydroxy-5-[(1R,S)-1-hydroxy-2-][(1R,S)-2-(p-methoxyphenyl)-l-methylethylamino]formanilide prepared as the fumarate dihydrate salt. Its structural features allow a high selectivity, intrinsic activity, and very high affinity at the β2-adrenoceptor. Relatively high water solubility and moderate lipophilicity ensure rapid access of inhaled FORM to the β2-adrenoceptor on bronchial smooth muscle cells and rapid bronchodilation. In contrast to the LABA SALM, the uptake of FORM by airway smooth muscle cells is dependent on organic cation transporter 3. The lipophilicity of FORM also explains its prolonged duration of action, and the possibility to be stored in cell membranes, making a depot from which the drug is available to β2-adrenoceptors on bronchial smooth muscle cells. The reported pKi (negative logarithm of the equilibrium dissociation constant of a ligand determined in inhibition studies) for FORM are from 6.07±0.04 to 6.12±0.09 and from 7.84±0.05 to 8.29±0.03, for β1 and β2 receptors, respectively, while the intrinsic activity (% isoprenaline) varies between 90 to 100, depending on the reports. FORM also has the highest bronchoselectivity compared with β2-adrenoceptor agonists isoproterenol, orciprenaline, trimetoquinol, and albuterol. The functional selectivity (ratio β1:β2) of FORM ranges from 1:13 to 1:166 and SALM from 1:525 to 1:3,000.

The bronchodilator effect of FORM in animal models was the most potent compared with other four β2-adrenoceptor agonists (isoproterenol, orciprenaline, trimetoquinol, and albuterol), after either subcutaneous, oral, or aerosol administration. FORM’s high affinity for β2-adrenoceptors and high intrinsic efficacy are also responsible for dose-related inhibition of histamine-induced bronchoconstriction, being 10- to 20-fold more potent than either albuterol or...
SALM.

In vitro and in vivo studies have shown that FORM has a fast onset of action that occurs within minutes after inhalation, comparable to that of albuterol and faster than SALM. Fast onset of action was described for FORM 12 µg (Modulite®) administered alone or in combination with TIO 18 µg during mild and moderate COPD acute exacerbations. The duration of action of FORM, approved as a BID administration of LABA, is longer than that of albuterol but markedly shorter than that of SALM.

**Pharmacokinetics and pharmacodynamics of GLY**

GLY, the active moiety of its bromide salt glycopyrrolate, is an antimuscarinic drug, first approved by the Food and Drug Administration (FDA) for the management of sialorrhea due to preoperative stages, neuromuscular and drug-related diseases, and gastric secretions. It is a quaternary ammonium derivative initially approved by FDA, European Medicines Agency, and in Japan as a monotherapy for COPD. In Europe, GLY was approved with a OD posology, whereas in the USA the BID regimen is recommended. Recently, FDA approved its BID posology in combination with fluticasone at a dosage of 9 µg BID delivered with a pressurized metered-dose inhaler (pMDI) formulation. GLY is rapidly absorbed into the systemic circulation after inhalation, ≈90% via lung and ≈10% via gastrointestinal absorption.

The mean terminal elimination half-life (t1/2) of GLY in dry powder inhaler formulations is half that reported for GLY delivered by pMDI (from 13 to 22 hours for a dose range of 25 to 200 µg and from 6.3 to 9.6 hours for a dose range of 14.4 to 115.2 µg, respectively).

GLY is a competitive muscarinic receptor antagonist that bronchodilates the airways by inhibiting acetylcholine-induced bronchoconstriction in bronchial smooth muscle cells.

The three main muscarinic receptors related to human lung bronchial dynamics are the M1, M2, and M3 receptors. M2 receptor protects against bronchoconstriction and its block may increase heart rate. M1 and, especially, M3 receptors are thought to be the prime mediators of the vagal-induced bronchoconstriction. In vitro, GLY has 4- to 5-fold higher selectivity for human M1 and M3 receptors compared with M2 receptor. GLY has a faster onset of action in both in vitro and in vivo animal models compared with TIO. The lower equilibrium binding affinity constants and the faster kinetic off rate justify the faster onset of action in patients with moderate to severe COPD compared with tiotropium bromide. In patients with severe COPD, GLY showed a fast and comparable ability to improve static lung volumes compared with aclidinium.

GLY has been shown to be more potent than ipratropium bromide and tiotropium bromide in terms of concentration drug necessary to inhibit the contractile response by 50%.

**Pharmacokinetics and pharmacodynamics of BDP**

BDP is the dipropionate ester of the free form beclomethasone-17-monopropionate, a synthetic halogenated glucocorticoid. BDP is a prodrug that must be activated through enzymatic processes in the lungs. Despite its higher oral availability compared with other ICSs, its prodrug form reduces the risk of local pharyngeal side effects, while it may favor a better pulmonary targeting, with 95% of beclomethasone that reaches the lung being transformed in its active form BDP delivered by pMDI has showed one of the highest lung deposition rates, reaching >50% of the delivered dose.

BDP has the lower known receptor affinity among mostly used ICSs. Given the binding ability of dexamethasone as 100, BDP has 53, while for comparison, salmeterol has a receptor affinity of 1,800. Although a higher affinity may signify higher potency, and thus, the possibility to employ lower dosages to exert the desired effect, a higher binding ability, may promote adverse effects. Nonetheless, given different binding affinities, ICSs may exert similar pulmonary targeting and thus similar anti-inflammatory effects.

**Interaction and advantages of triple combination therapy**

The small airways are the major and earlier site of lung damage in COPD, and their dysfunction is responsible for pathophysiological effects that withstand respiratory symptoms such as dyspnea, airway hyper-responsiveness, and exercise limitation. Both LABAs and LAMAs have demonstrated beneficial effects in terms of reduction in air trapping, closing volume, and airway stretching, especially when administered together. The rationale of combining a LABA and a LAMA relies on the synergistic effect exerted by the two classes of bronchodilators at the pre-junctional and intracellular levels. In fact, the stimulation of pre-junctional β2-receptors both reduce the intracellular calcium concentration, thus reducing the release of acetylcholine, and stimulate adenylyl cyclase that indirectly allows the release of acetylcholine in the synaptic space. On the contrary, LAMAs inhibit M3 receptors and amplify the bronchodilation induced...
by LABAs. Moreover, more complex additive effects are elicited through the intracellular crosstalk between M3, M2, and β2-receptors. However, low and iso-effective concentrations are needed in order to express a significant additive bronchodilation effect on the airways, the latter being more a class effect rather than being linked to a specific molecule.  

A dose–response trial that evaluated the most effective concentration of extra fine GLY added to extra fine BDP/FORM 200/12 µg FDC daily demonstrated that the dose of 25 µg exerts the ideal dose–effect in bronchodilation when compared with BDP/FORM alone and GLY doses of 12.5 and 50 µg.  

In addition, the combination of FORM and BDP proved to have a strong synergistic effect at very low doses (6 and 100 µg, respectively) in small hyper-responsive human airways. Despite the great technological evolution during recent years, inhaled drug deposition is jeopardized by lung ventilation inhomogeneity, unpredictable regional airflow obstruction characteristics, and the impacts of majority of inhaled drugs in the larger airways. The possibility of a synergistic effect at very low doses becomes crucial when considering the bronchodilator and anti-inflammatory effects exerted at the small airway level. In fact, the increased small particle fraction granted by the pMDI formulation of BDP/FORM/GLY should promote a better peripheral drug deposition, thus allowing for clinical effectiveness despite the small absolute amount of active drug.  

Although currently no in vitro study has evaluated the iso-effectiveness and the proportionality of the GLY and FORM dosages in the triple FDC, the effects of the triple therapy observed in patients with recurrent exacerbations and a consistent small airway damage represent a first evidence of the balance and functionality of this combination. While the synergistic effect of the combination of aclidinium and FORM or GLY and IND has been proven in in vitro and translational studies, this is not true for the combination of vilanterol (VI, under-dosed) and umeclidinium (UMEC, over-dosed).  

**Triple therapy for the management of moderate/severe exacerbations**

The TRILOGY, FULFIL, and TRINITY studies were the three RCTs that evaluated the efficacy of FDC triple therapy in COPD for the first time.

TRIBUTE and IMPACT were recently published and add new important information about this therapeutic approach to COPD treatment. The TRILOGY, TRINITY, and TRIBUTE trials compared the efficacy of the FDC of BDP/FORM/GLY 100/6/12.5 µg with the FDC of BDP/FROM (TRILOGY), the free combination of BDP/FORM with TIO or TIO alone (TRINITY), and the FDC of the LABA/LAMA IND/GLY (TRIBUTE). The FULFIL trial compared the efficacy of the FDC of fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) 100/62.5/25 µg with the FDC of BUD/FROM, while the IMPACT study compared the FF/UMEC/VI FDC with the LAMA/LABA FDC UMEC/VI and the ICS/LABA FDC FF/VI.

TRILOGY was a randomized, parallel group, double-blind, active-controlled study performed in 159 sites across 14 countries that compared the efficacy of the combination of ICS/LABA/LAMA, namely BDP/FORM/GLY in one inhaler with the fixed combination of BDP/FORM over 52 weeks.

FULFIL trial was a Phase III, randomized, double-blind, double-dummy, parallel group, multicenter study that compared the efficacy of the combination in one inhaler of FF, UMEC, VI to BUD/FORM over 24 weeks. The study was designed to evaluate the efficacy in term of change of FEV₁ from baseline at 24 weeks in all randomized subjects. An extension of the study up to 52 weeks was intended in a subgroup of patients for safety purposes.

TRINITY was a randomized, parallel group, double-blind, double-dummy, active-controlled 1-year trial, performed in 224 sites across 15 countries that compared the efficacy of three different treatments: BDP/FORM/GLY FDC; TIO monotherapy; and the combination therapy with BDP/FORM added to TIO.

IMPACT was a randomized, double-blind, parallel-group, multicenter trial on Phase III that compared the efficacy over 52 weeks of OD combination of FF (100 µg), UMEC at the dose of 62.5 µg and VI (25 µg) on the combination of FF/VI or the combination of UMEC/VI.

TRIBUTE was a randomized, parallel group, double-blind, double-dummy, active-controlled Phase IIIb study that compared the effect of one inhaler combination of two bronchodilators, namely IND 85 µg/GLY 43 µg OD and one inhaler triple therapy with BDP/FORM/GLY nominal dose respectively of 100 µg/6 µg/9 µg BID.

The studies explored different aspects of the disease; TRILOGY and FULFILL set lung function and QoL as the primary outcomes and evaluated AECOPDs as secondary outcomes while TRINITY, IMPACT, and TRIBUTE evaluated moderate and severe AECOPDs as the main outcomes (Table 1).

TRILOGY study randomized 1,368 patients while 1,810 patients were included in the ITT population of the FULFIL study and 430 were included in the extension (EXT) population. Both the studies demonstrated that adding a LAMA to
different combinations of ICS/LABA improved lung function and QoL, but not dyspnea.\textsuperscript{18,19}

In the TRIOLOGY study, the percentage of patients who had moderate-to-severe AECOPD was lower with BDP/Form/GLY (31\%) than with BDP/Form (35\%). The adjusted annual rate of moderate-to-severe exacerbations was 0.41 for the BDP/Form/GLY group and 0.53 for the BDP/Form group, with a rate ratio of 0.77 (95\% CI 0.65–0.92; \(P=0.005\)), indicating a significant 23\% reduction in the exacerbation rate with BDP/Form/GLY. Subgroup analyses of patients with more than one AECOPD have shown a more consistent treatment effect, with a reduction rate of moderate/severe AECOPD of 33\% in patients treated with BDP/Form/GLY compared with the BDP/Form group (rate ratio 0.67 [95\% CI 0.48–0.94]; \(P=0.019\)), whereas a minor effect could be found in the subgroup of patients with a history of one exacerbation or less in the previous 12 months (RR 0.83 [95\% CI 0.67–1.02]; \(P=0.074\))).\textsuperscript{18}

Different from TRINITY and TRILOGY trials, the FULFIL inclusion criteria were based not solely on exacerbations history, but included patients who belonged to group D according to GOLD classification 2016, that is, either patients with a FEV\(_1\) <50\% predicted and increased symptoms or patients with ≥1 severe exacerbation or ≥2 mild/moderate AECOPD. In the ITT population, 65\% of patients had at least one moderate/severe exacerbation. The incidence rates of moderate/severe AECOPD over the 24-week treatment period were 10\% and 14\% for FF/UMEC/VI and BUD/Form, respectively. The mean annualized rates of moderate/severe exacerbations in the ITT population were 0.22 and 0.34 for FF/UMEC/VI and BUD/Form, respectively, while the reduction in the annualized rate was statistically significant for FF/UMEC/VI (35\%; 95\% CI 14\%–51\%; \(P=0.002\)).\textsuperscript{19} Patients treated with FF/UMEC/VI experienced AECOPDs less frequently leading to hospitalization (n=12, 1\%) compared with the BUD/Form treatment group (n=22, 2\%).\textsuperscript{19}

AECOPDs were the focus in the TRINITY, IMPACT, and TRIBUTE studies that were designed to evaluate the rate of moderate/severe AECOPDs as the primary endpoint. In the TRINITY study, the comparison was made between the triple therapy and the LAMA alone and not compared with ICS/LABA.\textsuperscript{20}

The results show that in the FDC triple therapy (BDP/Form/GLY) group, the exacerbation rates were 0.46 (0.41–0.51) per patient, while in the TIO arm were 0.57 (0.52–0.63) with an RR of 0.80 (95\% CI 0.69–0.92; \(P=0.0025\)). In the BDP/Form plus TIO in open, the exacerbation rate was 0.45 (0.39–0.52) with a lower RR compared with patients treated with TIO (RR 0.79; 95\% CI 0.66–0.94; \(P=0.0095\)).\textsuperscript{20} No difference was found with the FDC triple therapy (RR 1.01; 95\% CI 0.85–1.21; \(P=0.89\)).\textsuperscript{20}

The TRINITY study explored the effect of the inhaled treatment on exacerbation also in terms of the time to first moderate-to-severe exacerbation as a secondary endpoint.\textsuperscript{20} The results have shown that FDC triple therapy was able to prolong the time to the next exacerbation compared with TIO alone with a hazard ratio (HR) of 0.84 (95\% CI 0.72–0.97; \(P=0.0154\)).\textsuperscript{20} However, the effect was similar compared with the group treated with BDP/Form plus TIO in open (HR 1.06; 95\% CI 0.88–1.27; \(P=0.57\)).\textsuperscript{20}

TRIBUTE was a randomized, parallel group, double-blind, double-dummy, active-controlled Phase IIIb trial that compared the efficacy of the FDC of BDP/Form/GLY 100/6/12.5 \(\mu\)g two actuations BID with the LABA/LAMA FDC IND/GLY 85/43 \(\mu\)g OD.\textsuperscript{21} In the TRIBUTE trial, 87\% of the 764 patients assigned to the BDP/Form/GLY treatment group and 84\% of the 768 patients assigned to IND/GLY completed the study, with an adjusted rate ratio of moderate/severe AECOPD of 0.50 per patient per year (95\% CI 0.45–0.57) and 0.59 (95\% CI 0.53–0.67), respectively.\textsuperscript{22} After 52 weeks of treatment, the FDC triple therapy showed a 15\% reduction in moderate and severe exacerbation rate compared with the LABA/LAMA FDC, with an adjusted rate ratio of 0.85 (95\% CI 0.72–0.99; \(P=0.043\)).\textsuperscript{22} No significant differences in the exacerbation rate were found between the two treatment groups when moderate and severe exacerbations were analyzed separately. The annual exacerbation rate was significantly reduced by the FDC triple therapy in patient with ≥2% of peripheral eosinophils (RR 0.806; 95\% CI 0.644–0.978; \(P=0.029\)), and the trend was maintained considering the absolute cutoff of 200 eosinophils/\(\mu\)L (RR 0.806; 95\% CI 0.646–1.007; \(P=0.057\)).\textsuperscript{22} An increase rate of pneumonia was not present in patients treated with BDP/Form/GLY, while atrial fibrillation was more frequently observed in the IND/GLY group.\textsuperscript{22}

The IMPACT was a Phase III, randomized, double-blind, parallel-group, multicenter trial. The primary outcome was the effect of the FDC of FF/UMEC/VI 100/62.5/25 \(\mu\)g OD compared with the LABA/LAMA combination of UMEC/VI 100/25 \(\mu\)g OD and the ICS/LABA FDC of FF/VI 100/25 \(\mu\)g OD in terms of moderate or severe AECOPD rate after 52 weeks of treatment. Patients were enrolled if they had a COPD assessment test (CAT) score ≥10 and either a FEV\(_1\) <50\% predicted and a history of at least
Triple therapy and severe acute exacerbations of COPD

one moderate or severe exacerbation in the previous year, or a FEV$_1$ between 50% and 80% predicted and at least two moderate exacerbations or one severe exacerbation in the previous year. At the end of the study period, the rate of moderate or severe exacerbations in triple therapy group was 0.91 per year compared with an annual rate of 1.07 for the FF/VI group (RR 0.85; 95% CI 0.80–0.90; $P<0.001$) and 1.21 in the UMEC/VI group (RR 0.75; 95% CI 0.70–0.81), suggesting a significant reduction in the rate of moderate and severe AECOPDs of 15% and 25%, respectively.

Considering severe AECOPDs only, the latter were low and the annual rate did not significantly differ (0.13 vs 0.15) between the triple therapy groups compared with the group treated with ICS/LABA (RR 0.87; 95% CI 0.76–1.01; $P=0.06$). However, a statistically significant 35% reduction ($P<0.001$) in severe exacerbations was reached comparing the effect of triple FDC with the LAMA/LABA UMEC/VI (RR 0.66; 95% CI 0.56–0.78). Concurrently, patients with $>150$ eosinophil/$\mu$L showed a not significant trend in reduction of moderate/severe exacerbations when treated with triple therapy in FDC$^{21}$ (Figure 1).

The annual rate of pneumonia was significantly increased in patient treated with FF-containing regimens. The time to the first pneumonia event in patients treated with the FDC triple therapy and in the UMEC/VI group differed significantly (RR 1.53; 95% CI 1.22–1.92; $P<0.001$), while no difference was found between the ICS-containing regimens.$^{21}$ One of the main limitation of the study was the inclusion of a significant number of patients with an asthmatic trait, since 18% of the study sample had a significant reversibility defined as an increase of 12% and 200 mL from baseline after an acute bronchodilation test.$^{67}$

**Perspective**

Making a research on ClinicalTrials.gov using the keywords “Chronic Obstructive Pulmonary Disease” and “Exacerbation” with the filter “Recruiting” and “not yet Recruiting” studies, by May 2018, we found 123 studies; of these, 11 evaluate the impact of inhaled treatments on AECOPDs and four are focused on triple therapy.

The SOPHOS study (NCT02727660)$^{68}$ is a Phase III randomized, double-blind, parallel group, multicenter, 1-year...
trial completed in April 2018. It evaluates the effect of different doses of BUD/FORM delivered via pMDI compared with FORM alone on the reduction of mild, moderate, and severe exacerbations in COPD patients with severe airflow obstruction. At the moment, no study results are available.

TRIVERSYTI (NCT03197818) is an ongoing 24-week, double-blind, double-dummy, randomized, multinational, multicenter, two-arm parallel group, actively controlled clinical trial that compares the efficacy of the FDC BDP/FORM/GLY delivered via pMDI with the FDC BUD/FORM in terms of lung function and time to first exacerbation in patients with severe COPD.

Finally, ETHOS (NCT02465567) and AIRWISE (NCT03265145) compare the effect of adding an ICS to a LABA/LAMA FDC treatment in the reduction of moderate/severe AECOPD in severe COPD patients. The ETHOS study tests different doses of the FDC of BUD/FORM/GLY with FF/GLY delivered via pMDI, while the AIRWISE study compares the TIO/olodaterol FDC with an ICS/LABA + LAMA regimen. The first study is planned to be completed by December 2018 and the second by January 2020.

Pharmacological prevention of moderate and severe COPD exacerbations

The triple therapy approach is one of the proposed options for the management of patients with frequent exacerbations. Although the initial strategy should be based upon treatment with a LABA/LAMA combination that had proved efficient in the reduction of mild and moderate AECOPDs, a definitive evidence on severe AECOPDs is still lacking. The evidence from trials investigating triple therapy regimens explored the effect of adding a second bronchodilator to an ICS/LABA regimen and the effect of adding an ICS to a LABA/LAMA treatment. Taken together, the results of the RCTs published so far show that there are good evidence that triple FDC therapy is superior to TIO alone in the prevention of moderate to severe AECOPD. The evidence on the prevention of AECOPDs from the TRILOGY18 and FULFIL19 trials seem to suggest that FDC triple therapy could reduce moderate and severe exacerbations more effectively than an ICS/LABA combination therapy. The effect seems to be more pronounced in patients with more than one moderate/severe AECOPD in the year preceding the enrolment. The IMPACT and TRIBUTE trials were specifically designed to explore the effect of a triple FDC therapy in the reduction of moderate and severe exacerbations in patients with a severe airflow obstruction and with a significant history of exacerbations. Data from these two large trials indicate a positive effect of the triple combination therapy in terms of reduction in moderate/severe exacerbations as a whole. However, when comparing the triple FDC with LABA/LAMA in the reduction of severe exacerbations, data are discordant. In fact, while patients treated with the FF/UMEC/VI FDC were less exposed to severe AECOPDs when compared with patients treated with the UMEC/VI regimen, the same was not apparent when comparing the effects of BDP/FORM/GLY and IND/GLY FDCs. The percentage of frequent exacerbators (patients with ≥2 exacerbations in the previous year) in the IMPACT trial was around 47% in each treatment arm, while the latter was low as 20% and 18% in the BDP/FORM/GLY and IND/GLY arms in the TRIBUTE trial. This large difference in the characteristics of the study populations between the two trials may have hindered the possible differences between the ICS/LABA/LAMA and LABA/LAMA in terms of reduction in severe exacerbations in the TRIBUTE study.

Confirming previous observations, the effect of the triple therapy in the IMPACT trial seemed to be independent of the peripheral eosinophil level. On the contrary, results from the TRIBUTE trial suggest that patients with ≥2% of serum eosinophils could respond better to an FDC triple therapy in the prevention of exacerbations. Recent evidence from the SUNSET trial shows that stepping down from triple therapy to a LAMA/LABA combination in non-frequent exacerbators can be safe in patients with an eosinophil count ≤300 cells/µL, while patients with higher eosinophil concentration may experience a larger decrease in lung function and a slightly higher risk of future exacerbation. Based on these results, eosinophils may still have a role in the decision-making for long-term COPD treatment, but, as also previously stated by Calverley, the most important and consistent parameter seems to be the history of moderate and severe exacerbations in patients already treated with a LABA/LAMA therapy. No less importantly, data from the IMPACT study confirm the possible increased risk of pneumonia in patients treated with fluticasone-containing inhaled regimens.

Author contributions

All authors contributed toward data analysis, drafting and revising the paper and agree to be accountable for all aspects of the work.

Disclosure

MM has received reimbursement for travel and conference participation by Boehringer Ingelheim, Menarini, AstraZeneca and payment for teaching in training course by Guidotti, Malesci,
and Grifols. DR has received speaker honoraria from Boehringer Ingelheim and AstraZeneca. PS received grants and personal fees from Chiesi Farmaceutici and Boehringer Ingelheim; grants from Air Liquide, Pfizer, and Almirall; and personal fees from AstraZeneca, GSK, Novartis, Menarini, Malesci, Guidotti, Mundipharma, and Zambon. FB received speaker or consultant honoraria or research funding from Menarini, Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi Farmaceutici, Dompe, GlaxoSmithKline, Lab. Guidotti, Malesci, Mundipharma, Novartis, Pfizer, Teva, Valeas, and Zambon. The authors report no other conflicts of interest in this work.

References


